Golden Diagnostics
Raghu Kannan
“THE NEW GOLD STANDARD IN
COMPANION DIAGNOSTICS”
Introductory Slide
Current methods of detectionIHC: Dako –in accuratePCR –amplifies all genes FISH –works well; however, microscopic visualization of tumor regions is difficult
First Target: NSCLCQuantify proteinsQuantify genesEffective treatment plan
Detects and quantifies proteins in tumor tissue.
Unmet Market or Clinical Need
Lung Cancer (2014) Incidence 221,200; Mortality: 158,040
The heterogeneity of NSCLC makes effective treatment dependent on knowledge of the patient’s tumor biomarkers (and mutations)
Cost of targeted therapy: $100,000
A diagnostic test platform that enables identification and quantitation of all types of tumor biomarkers (and mutation) is needed
Value Proposition
Platform Technology: Gold nanorod mediated targeted histochemistry” (GNR-HC).
Can identify and precisely quantify biomarkers in human tissues Highly sensitive.Can detect and quantify all classes of tumor biomarkers (e.g., proteins, mutations, gene fusion, copy number variants)
Business Model / Customer Development / Delivering Your SolutionBusiness model.
Diagnostic kit supplied to pathology laboratories.Oncologists –order to provide effective treatment plan.Pharmaceutical companies use as companion diagnostics.
Market strategyStart up: Golden DiagnosticsIDE; PMA pathway$250K for Pre-IDE phase$1-$1.5 million for IDE and PMA approval
Intellectual Property / Proprietary Technology
Building Management Teams and Advisory Board / Network DevelopmentRaghu Kannan –Business
development and nanotechnologyCo-founder of three start-ups; raised more than $3 million in funding.
Gerald Arthur –Board Certified PathologistPartners and potential partners
Regulatory specialists –Dr. Anandhi UpendranIndustry contacts –Eli Lilly for providing human samples and expertise
Financial Projections and Milestones